|  |
| --- |
| **SUPPLEMENTAL DATA** |
| **Combinations of PI3Kδ inhibitor idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma** | |
| Sven de Vos,1 Nina D. Wagner-Johnston,2 Steven E. Coutre,3 Ian W. Flinn,4 Marshall T. Schreeder,5 Nathan H. Fowler,6 Jeff P. Sharman,7 Ralph V. Boccia,8 Jacqueline C. Barrientos,9 Kanti R. Rai,9 Thomas E. Boyd,10 Richard R. Furman,11 Yeonhee Kim,12 Wayne R. Godfrey,12 John P. Leonard11 | |

**Supplemental Table 1. Subgroup nomenclature and doses.**

| **Analysis Group** | **Cohort** | **Abbreviation** | **Study Drug** | **Concomitant Treatment** | **Dosing**  **Schedule** | **N** |
| --- | --- | --- | --- | --- | --- | --- |
| Id+R | 1a | Id1+R | Idelalisib 100 mg BID | Rituximab 375 mg/m2 | Days 1,8,15 & 22, Cycles 1 & 2 | 12 |
| 2a | Id2+R | Idelalisib 150 mg BID | Rituximab 375 mg/m2 | Days 1,8,15 & 22, Cycles 1 & 2 | 12 |
| 3e | Id2+R | Idelalisib 150 mg BID | Rituximab 375 mg/m2 | Days 1,8,15 & 22, Cycles 1 & 2 | 12 |
| 4a | Id21+R | Idelalisib 150 mg BID (starting on Cycle 2, Day 1) | Rituximab 375 mg/m2 | Days 1,8,15 & 22, Cycles 1 & 2 | 12 |
| Id+B | 1b | Id1+B1 | Idelalisib 100 mg BID | Bendamustine 90 mg/m2 | Days 1 & 2, Cycles 1-6 | 12 |
| 2b | Id2+B1 | Idelalisib 150 mg BID | Bendamustine 90 mg/m2 | Days 1 & 2, Cycles 1-6 | 12 |
| 3f | Id2+B1 | Idelalisib 150 mg BID | Bendamustine 90 mg/m2 | Days 1 & 2, Cycles 1-6 | 6 |
| 4b | Id23+B1 | Idelalisib 150 mg BID (starting on Cycle 2, Day 3) | Bendamustine 90 mg/m2 | Days 1 & 2, Cycles 1-6 | 12 |
| Id+BR | 3a | Id2+B1R | Idelalisib 150 mg BID | Bendamustine 90 mg/m2  Rituximab 375 mg/m2 | Days 1 & 2, Cycles 1-6  Day 1,  Cycles 1-6 | 12 |

**Supplemental Table 2. Incidence of all SAEs, rituximab subgroups.**

| **SAE by Preferred Term** | **Group id1+R (N=8)** | **Group id2+R (N=12)** | **Group id21+R (N=12)** |
| --- | --- | --- | --- |
| **Subjects With Any SAE** | 5 (62.5 %) | 5 (41.7 %) | 5 (41.7 %) |
| Pneumonia | 0 ( 0.0 %) | 2 (16.7 %) | 1 ( 8.3 %) |
| Diarrhoea | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Renal failure acute | 0 ( 0.0 %) | 1 ( 8.3 %) | 1 ( 8.3 %) |
| Cardiac arrest | 1 (12.5 %) | 1 ( 8.3 %) | 0 ( 0.0 %) |
| Herpes zoster | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Bronchitis | 0 ( 0.0 %) | 1 ( 8.3 %) | 0 ( 0.0 %) |
| Cerebral ischaemia | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Cholecystitis acute | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Colitis | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Crohn's disease | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Cytomegalovirus | 0 ( 0.0 %) | 1 ( 8.3 %) | 0 ( 0.0 %) |
| Decreased appetite | 0 ( 0.0 %) | 1 ( 8.3 %) | 0 ( 0.0 %) |
| Hepatic enzyme increased | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Hyperuricaemia | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Intestinal obstruction | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Lung infection | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Peptic ulcer | 0 ( 0.0 %) | 1 ( 8.3 %) | 0 ( 0.0 %) |
| Rash | 0 ( 0.0 %) | 1 ( 8.3 %) | 0 ( 0.0 %) |
| Small intestinal obstruction | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Squamous cell carcinoma | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Subdural haematoma | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Transaminases increased | 0 ( 0.0 %) | 1 ( 8.3 %) | 0 ( 0.0 %) |
| Urinary tract infection | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |


**Supplemental Table 3. Incidence of SAEs, bendamustine subgroups.**

| **AE by Preferred Term** | **Group id1+B1 (N=8)** | **Group id2+B1 (N=13)** | **Group id23+B1 (N=12)** |
| --- | --- | --- | --- |
| **Subject With SAE** | 8 ( 100 %) | 8 (61.5 %) | 8 (66.7 %) |
| Pneumonia | 3 (37.5 %) | 7 (53.8 %) | 0 ( 0.0 %) |
| Pyrexia | 5 (62.5 %) | 1 ( 7.7 %) | 1 ( 8.3 %) |
| Febrile neutropenia | 2 (25.0 %) | 1 ( 7.7 %) | 2 (16.7 %) |
| Diarrhoea | 0 ( 0.0 %) | 2 (15.4 %) | 1 ( 8.3 %) |
| Sepsis | 0 ( 0.0 %) | 4 (30.8 %) | 0 ( 0.0 %) |
| Renal failure acute | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Herpes zoster | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Hypokalaemia | 0 ( 0.0 %) | 1 ( 7.7 %) | 1 ( 8.3 %) |
| Pneumonitis | 1 (12.5 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Acute myeloid leukemia | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Acute respiratory | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Anaemia | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Arthralgia | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Cerebrovascular ac | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Drug eruption | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Escherichia bacteria | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Fall | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Fatigue | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Gastrointestinal obstruction | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Hypersensitivity | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Hypotension | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Influenza | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Lactic acidosis | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Malnutrition | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Meningitis | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Mental status change | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Myalgia | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Myocardial infarction | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Neutropenia | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Non-hodgkin's lymphoma | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Oesophageal squamous | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Pancytopenia | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Pelvic pain | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Pneumococcal sepsis | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Pneumonia haemophilia | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Pneumonia influenza | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Septic shock | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Supraventricular tachycardia | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Syncope | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Tachycardia | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Thrombocytopenia | 1 (12.5 %) | 0 ( 0.0 %) | 0 ( 0.0 %) |
| Upper respiratory | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Ventricular tachycardia | 0 ( 0.0 %) | 1 ( 7.7 %) | 0 ( 0.0 %) |
| Vomiting | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |
| Weight decreased | 0 ( 0.0 %) | 0 ( 0.0 %) | 1 ( 8.3 %) |


**Supplemental Table 4. Subgroup response rates.**

| **Treatment** | **CR** | **PR** | **SD** | **PD** | **NE** | **ORR** |
| --- | --- | --- | --- | --- | --- | --- |
| Id1+R | 2 | 5 | 1 | 0 | 0 | 87.5% |
| Id2+R | 2 | 8 | 1 | 0 | 1 | 83.3% |
| Id21+R | 2 | 4 | 3 | 2 | 1 | 50.0% |
| Id1+B1 | 1 | 6 | 1 | 0 | 0 | 87.5% |
| Id2+B1 | 5 | 7 | 1 | 0 | 0 | 92.3% |
| Id23+B1 | 3 | 7 | 1 | 1 | 0 | 83.3% |


**Supplemental Figure 1A. Progression-free survival, rituximab subgroups**

****


**Supplemental Figure 1B. Duration of response, rituximab subgroups**

****

**Supplemental Figure 2A. Progression-free survival, bendamustine subgroups**

****

**Supplemental Figure 2B. Duration of response, bendamustine subgroups**

****